Log in

Relevant bibliographies by topics / Angiotensine II – Antagonistes / Books

To see the other types of publications on this topic, follow the link: Angiotensine II – Antagonistes.

Books on the topic 'Angiotensine II – Antagonistes'

Author: Grafiati

Published: 4 June 2021

Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 17 books for your research on the topic 'Angiotensine II – Antagonistes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Philipp, Th, and R. F. Schäfers, eds. Angiotensin II — Antagonismus. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79645-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Parker, James N., and Philip M. Parker. Diovan: A medical dictionary, bibliography, and annotated research guide to internet references. San Diego, CA: ICON Health Publications, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mancia, Giuseppe, ed. Angiotensin II Receptor Antagonists. CRC Press, 2006. http://dx.doi.org/10.1201/9780367804152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mancia, Giuseppe, ed. Angiotensin II Receptor Antagonists. CRC Press, 2006. http://dx.doi.org/10.1201/b14355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

(Editor), Murray Epstein, and Hans R. Brunner (Editor), eds. Angiotensin II Receptor Antagonists. Hanley & Belfus, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Angiotensin II Receptor Antagonists In Perspective. Taylor & Francis, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Leyva, F. The Angiotensin II Receptor Antagonists Compendium. Current Medical Literature, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Giuseppe, Mancia, ed. Angiotensin II receptor antagonists: Current perspectives. 2nd ed. Abingdon [England]: Informa Healthcare, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

McInnes, G. T. Pocket Reference to Angiotensin II Antagonists. Science Press, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

(Editor), Naranjan S. Dhalla, Peter Zahradka (Editor), Ian M.C. Dixon (Editor), and Robert E. Beamish (Editor), eds. Angiotensin II Receptor Blockade: (Progress in Experimental Cardiology). Springer, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

S, Dhalla Naranjan, and Manitoba Cardovascular Forum on Angiotensin Receptor Blockade (1996 : Winnipeg, Man.), eds. Angiotensin II receptor blockade: Physiological and clinical implications. Boston: Kluwer Academic Publishers, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mancia, Guiseppe. Angiotensin II Receptor Antagonists: Current Perspectives, Second Edition. 2nd ed. Informa Healthcare, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

(Editor), T. Philipp, and R. F. Schäfers (Editor), eds. Angiotensin II: Antagonismus: Ein neuer Weg zur Hochdruckbehandlung. Springer, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ramrakha, Punit, and Jonathan Hill, eds. Drugs for the heart. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199643219.003.0002.

Full text

Abstract:

Antiplatelet agents 82Antiplatelet agents: aspirin 84Antiplatelet agents: thienopyridines 88Antiplatelet agents: clopidogrel 90Antiplatelet agents: prasugrel 94Intravenous antiplatelet agents 96Angiotensin-converting enzyme inhibitors 98Angiotensin receptor blockers (ARBs, also referred to as angiotensin II receptor antagonists, AIIRAs) 102Aldosterone antagonists 106Beta-adrenoceptor blockers (...

APA, Harvard, Vancouver, ISO, and other styles

15

K, Ferguson Roger, and Vlasses Peter, eds. Angiotensin-converting enzyme inhibitors. Mount Kisco, N.Y: Futura Pub. Co., 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Phipps, Lisa M., Titi Chen, and David C. H. Harris. Radiation nephropathy. Edited by Adrian Covic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0091_update_001.

Full text

Abstract:

Radiation nephropathy usually arises after inadvertent exposure of kidneys to radiotherapy. It may manifest as acute nephropathy as early as 6 months after exposure, or later as chronic nephropathy, hypertension, or asymptomatic proteinuria. Glomerular and peritubular endothelium and renal tubular cells are especially radiosensitive. There are no pathognomonic histological features, but renal pathology may be similar to that of haemolytic uraemic syndrome. Radiation nephropathy may be prevented by renal shielding and mitigated by radiation dose fractionation. Control of hypertension is important and angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists appear to have protective effects beyond those of blood pressure control.

APA, Harvard, Vancouver, ISO, and other styles

17

Hider, Samantha, and Edward Roddy. Epidemiology of gout. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199668847.003.0038.

Full text

Abstract:

Gout is the most prevalent inflammatory arthritis in men. Data from epidemiological studies conducted in several countries suggest that the prevalence and incidence of gout have risen over the last few decades, although incidence may have stabilized recently. Dietary factors (animal purines, alcohol, and fructose), co-morbid medical conditions (obesity, metabolic syndrome, hypertension, and chronic kidney disease), and medications (diuretics, aspirin, beta blockers, angiotensin converting-enzyme inhibitors, and non-losartan angiotensin II receptor blockers) have been confirmed to be risk factors for both hyperuricaemia and gout. In contrast, low-fat dairy products, coffee, vitamin C, calcium channel antagonists, and losartan appear to reduce the risk of developing gout. People with gout are themselves at increased risk of developing cardiovascular disease and chronic kidney disease, independent of traditional risk factors for these conditions.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!